2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13C.05 Factors Affecting Outcomes of Limited Stage (IIB-IIIC) Small Cell Lung Cancer: An Analysis of the National Cancer Database.

EP.13C.05 Factors Affecting Outcomes of Limited Stage (IIB-IIIC) Small Cell Lung Cancer: An Analysis of the National Cancer Database.

Back to course

Pdf Summary

This study examines the factors affecting outcomes in patients with limited-stage small cell lung cancer (SCLC), specifically stages IIB and IIIC (T1-T2, N0, M0), using data from the National Cancer Database. The research focused on patients diagnosed between 2010 and 2020 and analyzed various demographic and treatment factors impacting overall survival (OS).<br /><br />Key findings include:<br /><br />1. <strong>Age and Sex</strong>: Patients aged 75 years or older had worse OS compared to younger groups. Specifically, patients aged 65-75 had a hazard ratio (HR) of 1.10, while those aged 75 or older had an HR of 1.26. Male patients also faced worse outcomes, with an HR of 1.15.<br /><br />2. <strong>Race and Insurance</strong>: Better OS was noted among Caucasians (HR 0.67), African Americans (HR 0.62), and other races including Hispanics and Asian Americans (HR 0.51), as opposed to Native Americans. Patients with private insurance exhibited better survival rates compared to those with Medicare or without insurance (HR 0.91).<br /><br />3. <strong>Treatment and Diagnosis Timeline</strong>: Patients diagnosed between 2010-2015 experienced poorer survival rates (HR 1.20). The study revealed that those who received sequential chemotherapy and radiation had a median OS of 23.3 months, significantly longer than the 17.4 months for patients who underwent concurrent chemoradiation, contrary to previous findings.<br /><br />4. <strong>Overall Survival</strong>: Median OS varied across age groups, registering 14.0 months for those younger than 65, 12.65 months for age 65-75, and 6.01 months for those 75 and older.<br /><br />The research underscores the importance of considering demographic factors and treatment type in managing limited-stage SCLC and suggests a potential re-evaluation of treatment strategies, particularly the use of sequential chemoradiation for improved patient outcomes.

Asset Subtitle

Hafez Abdullah

Meta Tag

Speaker Hafez Abdullah

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

small cell lung cancer

limited-stage SCLC

National Cancer Database

overall survival

age and sex

race and insurance

treatment timeline

sequential chemoradiation

demographic factors

treatment strategies